Please select the option that best describes you:
Topics:
Hematologic Malignancies • General Internal Medicine • Thrombosis • Hematology • Benign Hematology • Hemostasis/Thrombosis • MGUS
What is your clinical threshold for treating a potential monoclonal gammopathy of thrombotic significance?
New data suggests monoclonal gammopathies can be associated with thrombotic events. Is your practice changing to include monoclonal gammopathy evaluations for new thrombosis? Or perhaps only for recurrent thrombosis or breakthrough thrombosis on therapeutic anticoagulation?
For older patients who are more likely to have a monoclonal gammopathy as well as other risk factors for thrombosis, how are you deciding when a patient has a monoclonal gammopathy of thrombotic significance vs true and unrelated MGUS and thrombosis?
Answer from: at Academic Institution
I strongly advise against routine screening for monoclonal gammopathy in patients with thrombosis. The incidence of MGUS, particularly in older patients, is relatively high and so the signal-to-noise ratio in this setting will be very low. In a patient with recurrent thrombosis and thrombocytopenia ...
Sign in or Register to read more